Published in J Virol on August 27, 2014
Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation. Mol Cell Proteomics (2015) 1.08
Analysis of Major Histocompatibility Complex (MHC) Immunopeptidomes Using Mass Spectrometry. Mol Cell Proteomics (2015) 1.05
Toxoplasma gondii peptide ligands open the gate of the HLA class I binding groove. Elife (2016) 0.88
Defining the HLA class I-associated viral antigen repertoire from HIV-1-infected human cells. Eur J Immunol (2015) 0.83
The Length Distribution of Class I-Restricted T Cell Epitopes Is Determined by Both Peptide Supply and MHC Allele-Specific Binding Preference. J Immunol (2016) 0.82
MR1-restricted mucosal-associated invariant T (MAIT) cells respond to mycobacterial vaccination and infection in nonhuman primates. Mucosal Immunol (2016) 0.81
The Intergenic Recombinant HLA-B∗46:01 Has a Distinctive Peptidome that Includes KIR2DL3 Ligands. Cell Rep (2017) 0.77
Analysis of Major Histocompatibility Complex-Bound HIV Peptides Identified from Various Cell Types Reveals Common Nested Peptides and Novel T Cell Responses. J Virol (2016) 0.75
Human Leukocyte Antigen F Presents Peptides and Regulates Immunity through Interactions with NK Cell Receptors. Immunity (2017) 0.75
Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol (1992) 12.89
Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature (2011) 9.30
Adaptation of HIV-1 to human leukocyte antigen class I. Nature (2009) 4.24
Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol (2005) 3.23
Immune clearance of highly pathogenic SIV infection. Nature (2013) 3.15
Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides. J Virol (2004) 2.21
Differential antigen presentation regulates the changing patterns of CD8+ T cell immunodominance in primary and secondary influenza virus infections. J Exp Med (2003) 2.07
TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection. Nat Immunol (2012) 2.04
De novo generation of escape variant-specific CD8+ T-cell responses following cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection. J Virol (2005) 2.04
Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. J Infect Dis (2010) 1.95
HIV and HLA class I: an evolving relationship. Immunity (2012) 1.91
Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines. Nat Med (2012) 1.86
Definition of the viral targets of protective HIV-1-specific T cell responses. J Transl Med (2011) 1.73
CD4(+) T-cell depletion in HIV infection: mechanisms of immunological failure. Immunol Rev (2013) 1.58
Have we cut ourselves too short in mapping CTL epitopes? Trends Immunol (2005) 1.41
A molecular basis for the control of preimmune escape variants by HIV-specific CD8+ T cells. Immunity (2013) 1.41
HLA-B57-restricted cytotoxic T-lymphocyte activity in a single infected subject toward two optimal epitopes, one of which is entirely contained within the other. J Virol (2000) 1.38
Development and validation of a fluorescence polarization-based competitive peptide-binding assay for HLA-A*0201--a new tool for epitope discovery. Biochemistry (2005) 1.26
Broadly neutralizing antibodies against HIV-1: templates for a vaccine. Virology (2013) 1.23
Development of prophylactic vaccines against HIV-1. Retrovirology (2013) 1.12
Correlates of resistance to HIV-1 infection in homosexual men with high-risk sexual behaviour. AIDS (2004) 1.10
Real-time measurement of in vitro peptide binding to soluble HLA-A*0201 by fluorescence polarization. Biochemistry (2004) 1.03
Early antigen presentation of protective HIV-1 KF11Gag and KK10Gag epitopes from incoming viral particles facilitates rapid recognition of infected cells by specific CD8+ T cells. J Virol (2012) 0.93
Escape from autologous humoral immunity of HIV-1 is not associated with a decrease in replicative capacity. Virology (2009) 0.93
HIV-specific cytotoxic T lymphocytes, HLA-A11, and chemokine-related factors may act synergistically to determine HIV resistance in CCR5 delta32-negative female sex workers in Chiang Rai, northern Thailand. AIDS Res Hum Retroviruses (2001) 0.91
Novel HIV vaccine strategies: overview and perspective. Ther Adv Vaccines (2013) 0.90
Direct class I HLA antigen discovery to distinguish virus-infected and cancerous cells. Expert Rev Proteomics (2006) 0.90
Short communication: association of HLA-A*1101 with resistance and B*4006 with susceptibility to HIV and HIV-TB: an in silico analysis of promiscuous T cell epitopes. AIDS Res Hum Retroviruses (2009) 0.89
Adaptor protein 1 promotes cross-presentation through the same tyrosine signal in major histocompatibility complex class I as that targeted by HIV-1. J Virol (2013) 0.87
Impact of mutations in highly conserved amino acids of the HIV-1 Gag-p24 and Env-gp120 proteins on viral replication in different genetic backgrounds. PLoS One (2014) 0.85
Critical factors in the development of fluorescence polarization-based peptide binding assays: an equilibrium study monitoring specific peptide binding to soluble HLA-A*0201. J Immunol Methods (2006) 0.83
A novel T-cell receptor mimic defines dendritic cells that present an immunodominant West Nile virus epitope in mice. Eur J Immunol (2014) 0.82
Different in vivo effects of HIV-1 immunodominant epitope-specific cytotoxic T lymphocytes on selection of escape mutant viruses. J Virol (2010) 0.82
A biochemical and structural analysis of genetic diversity within the HLA-A*11 subtype. Immunogenetics (2005) 0.79
HLA-associated susceptibility to acquired immune deficiency syndrome in HIV-1-seropositive subjects. Hum Hered (1990) 0.78
Refinement in the production and purification of recombinant HCMV IE1-pp65 protein for the generation of epitope-specific T cell immunity. Protein Expr Purif (2008) 0.77